Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
    
  
Aspirin for COVID-19
60 studies from 894 scientists
171,395 patients in 18 countries
Statistically significant improvement for mortality and progression.
11% lower mortality in 52 studies, 16% improvement in the REMAP-CAP RCT, and 17% for non-LMWH patients in the RECOVERY RCT
Benefit may be more likely without coadministered anticoagulants.
COVID-19 Aspirin studies. Nov 2022. c19early.org/e
0 0.5 1 1.5+ All studies 11% With exclusions 14% Mortality 11% Hospitalization -2% Recovery 9% Cases 10% Viral clearance 9% RCTs 5% RCT mortality 5% Prophylaxis 7% Early 67% Late 17% Favorsaspirin Favorscontrol
Aspirin COVID-19 studies. Benefit may be more likely without coadministered anticoagulants. Recent:
Ali
Zekri-Nechar
Ali
Baral
Geiger
Eikelboom
Eikelboom.
Aspirin has been officially adopted for early treatment in part of 1 country. Submit updates/corrections.
Nov 26
Covid Analysis (Preprint) (meta analysis) Aspirin for COVID-19: real-time meta analysis of 60 studies
Statistically significant improvements are seen for mortality and progression. 24 studies from 22 independent teams in 10 different countries show statistically significant improvements in isolation (19 for the most serious outcome). • ..
Nov 19
Ali et al., Chest, doi:10.1016/j.chest.2022.11.013 Cardiovascular complications are the primary drivers of mortality in hospitalized patients with SARS-CoV-2 community-acquired pneumonia
28% lower mortality [p=0.07]. Retrospective 1,645 hospitalized patients in the USA, showing lower mortality with aspirin use, without statistical significance.
Nov 15
Zekri-Nechar et al., Medicina, doi:10.3390/medicina58111649 Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
16% higher mortality [p=0.57] and 16% higher ICU admission [p=0.57]. Retrospective 201 consecutive elderly hospitalized patients in Spain, showing higher mortality with aspirin use in unadjusted results. The aspirin group was older and had higher prevalence of hypertension and dyslipidemia. Table 1 shows t..
Oct 31
Ali et al., Egyptian Journal of Anaesthesia, doi:10.1080/11101849.2022.2139104 Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID- 19
40% lower mortality [p<0.0001] and 37% lower ARDS [p=0.001]. Retrospective 1,190 ICU patients in Egypt, showing lower mortality with aspirin treatment. 150mg daily.
Oct 29
Baral et al., Biology Methods and Protocols, doi:10.1093/biomethods/bpac027 (meta analysis) All-cause and In-hospital Mortality after Aspirin Use in Patients Hospitalized with COVID-19: A Systematic Review and Meta-analysis
14% lower mortality [p=0.02]. Systematic review and meta analysis of 11 aspirin COVID-19 studies, showing lower in-hospital mortality with treatment.
Oct 10
Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00299-5 Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
9% higher mortality [p=0.84], 20% lower progression [p=0.21], and 17% lower hospitalization [p=0.31]. Late (5.4 days) outpatient RCT showing no significant difference in outcomes with aspirin treatment.
Oct 10
Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00298-3 Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
5% higher mortality [p=0.66] and 8% lower progression [p=0.32]. RCT very late stage (baseline SpO2 77%) patients, showing no significant differences with rivaroxaban and aspirin treatment.
Oct 10
Morrison et al., PLOS ONE, doi:10.1371/journal.pone.0275787 COVID-19 outcomes in patients taking cardioprotective medications
8% lower mortality [p=0.52], 1% higher ventilation [p=0.96], 12% higher ICU admission [p=0.36], and 18% higher hospitalization [p=0.04]. Retrospective 13,585 COVID+ patients in the USA, showing higher hospitalization with aspirin use, and no significant difference for mortality, ventilation, and ICU admission.
Oct 3
Karimpour-Razkenari et al., Journal of Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790 Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19
123% higher mortality [p=0.008]. Retrospective 478 moderate to severe hospitalized patients in Iran, showing higher mortality with aspirin treatment. Authors note confounding by indication for aspirin treatment.
Sep 27
Geiger et al., Vaccines, doi:10.3390/vaccines10101619 (In Vitro) Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices
In Vitro study showing that aspirin and metabolite salicylic acid inhibit SARS-CoV-2 viral replication in Vero, A549-ACE2, and Huh-7 cells, and in human precision-cut lung slices. Results indicate inhibition of post-entry pathways.
Aug 16
Loucera et al., medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint) Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk
18% lower mortality [p=0.0004]. Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide.
Aug 11
Srinivasan et al., American Heart Journal Plus: Cardiology Research and Practice, doi:10.1016/j.ahjo.2022.100191 (meta analysis) Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis
29% lower mortality [p=0.0003]. Meta analysis of 14 studies with 164,539 patients, showing lower mortality with aspirin.
Aug 4
Abul et al., medRxiv, doi:10.1101/2022.08.03.22278392 (Preprint) Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes
33% lower mortality [p=0.03] and 20% lower hospitalization [p=0.13]. Retrospective 1,687 nursing home residents in the USA, showing significantly lower risk of mortality with chronic low-dose aspirin use. Low dose 81mg aspirin users had treatment ≥10 of 14 days prior to the positive COVID date, control pat..
Jul 11
Malik et al., Health Science Reports, doi:10.1002/hsr2.699 Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID‐19, analytical cross‐sectional study
14% lower mortality [p=0.72], 28% lower ICU admission [p=0.17], 25% lower ARDS [p=0.39], and 2% lower hospitalization [p=0.94]. Retrospective 539 patients in the USA, showing lower mortality, ICU admission, and ARDS with aspirin treatment, without statistical significance.
Jul 9
Ghati et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07570-5 Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)
22% lower mortality [p=0.62], 9% lower ventilation [p=0.8], and 30% lower progression [p=0.46]. RCT hospitalized patients in India, 224 treated with atorvastatin, 225 with aspirin, and 225 with both, showing lower serum interleukin-6 levels with aspirin, but no statistically significant changes in other outcomes. Low dose aspirin 75..
Jun 22
Santoro et al., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530 Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry
38% lower mortality [p=0.02]. HOPE-COVID-19 PSM retrospective 7,824 patients, comparing prophylactic anticoagulation with and without additional treatment with aspirin in hospitalized patients, showing lower mortality with aspirin treatment.
Jun 17
Botton et al., Research and Practice in Thrombosis and Haemostasis, doi:10.1002/rth2.12743 No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease
4% higher combined mortality/intubation [p=0.18] and 3% higher hospitalization [p=0.05]. Retrospective 31 million people without cardiovascular disease in France, showing no significant difference in hospitalization or combined intubation/death with low dose aspirin prophylaxis.
May 30
Kumar et al., Cureus, doi:10.7759/cureus.25467 Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial
89% improved recovery [p=0.05]. RCT 260 patients in India, 130 treated with aspirin, promethazine, vitamin C, D, B3, zinc, and selenium, showing faster recovery with treatment. There was no hospitalization, ICU admission, or supplemental oxygen requirements in either gr..
May 5
Lal et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 (date from earlier preprint) Pre-hospital aspirin use and patient outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)
11% lower mortality [p=0.01], 22% lower ICU admission [p<0.0001], and 9% lower progression [p=0.02]. Retrospective 21,579 hospitalized COVID-19 patients mostly in the USA, showing lower risk of mortality and severity with existing aspirin use.
May 5
Campbell et al., PLOS ONE, doi:10.1371/journal.pone.0267462 Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19
3% lower mortality [p=0.06]. Retrospective 28,856 COVID-19 patients in the USA, showing no significant difference in mortality for chronic aspirin use vs. sporadic NSAID use. Since aspirin is available OTC and authors only tracked prescriptions, many patients classif..
May 2
Drew et al., medRxiv, doi:10.1101/2021.04.28.21256261 (Preprint) Aspirin and NSAID use and the risk of COVID-19
22% lower progression [p=0.3] and 3% more cases [p=0.8]. Retrospective 2,736,091 individuals in the U.S., U.K., and Sweden, showing lower risk of hospital/clinic visits with aspirin use.
Mar 24
Chow et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.3890 Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
13% lower mortality [p<0.0001]. Retrospective 112,269 hospitalized COVID-19 patients in the USA, showing lower mortality with aspirin treatment.
Mar 22
Bradbury et al., JAMA, doi:10.1001/jama.2022.2910 Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
16% lower mortality [p=0.05], 17% higher hospital discharge [p=0.08], and 21% lower progression [p=0.02]. RCT 1,557 critical patients, showing significantly lower mortality with aspirin, with 97.5% posterior probability of efficacy.
Mar 9
Gogtay et al., World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92 Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia
6% higher mortality [p=0.87], 50% lower ventilation [p=0.16], and 49% lower ICU admission [p=0.41]. Retrospective 125 COVID+ hospitalized patients in the USA, showing no significant differences with aspirin prophylaxis.
Feb 28
Nimer et al., Bosnian Journal of Basic Medical Sciences, doi:10.17305/bjbms.2021.7009 The impact of vitamin and mineral supplements usage prior to COVID-19 infection on disease severity and hospitalization
4% lower hospitalization [p=0.08] and 18% higher severe cases [p=0.28]. Retrospective survey based analysis of 2,148 COVID-19 recovered patients in Jordan, showing no significant differences in the risk of severity and hospitalization with aspirin prophylaxis.
Jan 31
Levy et al., Gerontology, doi:10.1159/000521412 Frail Older Adults with Presymptomatic SARS-CoV-2 Infection: Clinical Course and Prognosis
26% lower combined mortality/hospitalization [p=0.13]. Retrospective 849 COVID-19+ patients in skilled nursing homes, showing lower risk of combined hospitalization/death with aspirin prophylaxis, not reaching statistical significance.
Jan 24
de Jesús Ascencio-Montiel et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002 A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
59% lower combined mortality/hospitalization [p<0.0001], 15% lower mortality [p=0.16], 9% lower ventilation [p=0.51], and 48% lower hospitalization [p<0.0001]. Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment k..
Jan 8
Monserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078 A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
31% higher mortality [p=0.04]. PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine..
Jan 7
Sullerot et al., GeroScience, doi:10.1007/s11357-021-00499-8 Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia
10% higher mortality [p=0.52], 110% higher ICU admission [p=0.007], and 10% longer hospitalization [p=0.02]. Retrospective 1,047 pneumonia patients in 5 COVID-19 geriatric units in France and Switzerland, significantly higher ICU admission and longer hospital stays with existing aspirin treatment. Numbers in this study appear to be inconsistent,..
Dec 29
2021
Mustafa et al., Exploratory Research in Clinical and Social Pharmacy, doi:10.1016/j.rcsop.2021.100101 Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan
44% lower mortality [p=0.28]. Retrospective 444 hospitalized patients in Pakistan, showing lower mortality with aspirin treatment in unadjusted results, not reaching statistical significance.
Dec 24
2021
Banaser et al., International Journal of Medicine in Developing Countries, doi:10.24911/IJMDC.51-1640383699 (meta analysis) A systematic review and meta-analysis on efficacy of low dose aspirin on the management of COVID-19
49% lower mortality [p<0.0001] and 30% lower ventilation [p=0.006]. Meta analysis of 8 studies showing significantly lower mortality and mechanical ventilation with low dose aspirin.
Nov 18
2021
RECOVERY Collaborative Group, The Lancet, doi:10.1016/S0140-6736(21)01825-0 Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
4% lower mortality [p=0.35], 5% lower ventilation [p=0.32], 6% higher hospital discharge [p=0.006], and 11% shorter hospitalization. RCT 14,892 late stage patients, 7,351 treated with aspirin, showing slightly improved discharge and hospitalization time, and no significant difference for mortality. Results are limited due to low dose (150mg daily), very late treatment ..
Oct 14
2021
Santoro et al., European Heart Journal, doi:10.1093/eurheartj/ehab724.3002 Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19)
71% lower mortality [p<0.0001]. Retrospective database analysis of 7,824 patients in the HOPE-COVID19 registry, 730 receiving antiplatelet therapy including aspirin, showing lower mortality with treatment. Authors do not provide results restricted to aspirin.
Oct 11
2021
Connors et al., JAMA, doi:10.1001/jama.2021.1727283 Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
67% lower hospitalization [p=0.49] and 19% lower progression [p=0.78]. Early terminated RCT with 164 aspirin and 164 control patients in the USA with very few events, showing no significant difference with aspirin treatment for the combined endpoint of all-cause mortality, symptomatic venous or arterial thro..
Oct 4
2021
Pérez-Segura et al., Medicina Clínica, doi:10.1016/j.medcle.2021.02.010 Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
49% higher mortality [p=0.0001]. Retrospective 770 COVID-19 patients with cancer, showing increased mortality with aspirin use in unadjusted results.
Oct 4
2021
Sisinni et al., International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058 Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
7% higher mortality [p=0.65] and 30% lower combined mortality/intubation [p=0.01]. Retrospective 984 COVID-19 patients, 253 taking aspirin prior to admission, showing lower risk of respiratory support upgrade with treatment.
Oct 2
2021
Basheer et al., Metabolites, doi:10.3390/metabo11100679 Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia
13% higher mortality [p=0.0003]. Retrospective 390 hospitalized patients in Israel, showing higher risk of mortality with prior aspirin use. Details of the analysis are not provided.
Oct 1
2021
Zhao et al., Anesthesiology, doi:10.1097/ALN.0000000000003999 Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study
43% lower mortality [p=0.0006]. Retrospective 2,070 hospitalized patients in the USA, showing lower mortality with aspirin treatment.
Sep 4
2021
Kim et al., Medicina, doi:10.3390/medicina57090931 Aspirin Is Related to Worse Clinical Outcomes of COVID-19
700% higher mortality [p=0.03], 433% higher ventilation [p=0.14], 433% higher ICU admission [p=0.14], and 33% fewer cases [p=0.29]. Retrospective database analysis of 22,660 patients tested for COVID-19 in South Korea. There was no significant difference in cases according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin u..
Sep 3
2021
Al Harthi et al., Journal of Intensive Care Medicine, doi:10.1177/08850666221093229 Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study
27% lower mortality [p=0.03]. Retrospective 1,033 critical condition patients, showing lower in-hospital mortality with aspirin in PSM analysis. Patients receiving aspirin also had a higher risk of significant bleeding, although not reaching statistical significance. ..
Sep 1
2021
Karruli et al., Microbial Drug Resistance, doi:10.1089/mdr.2020.0489 Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience
46% lower mortality [p=0.63]. Retrospective 32 ICU patients showing lower mortality with aspirin treatment, without statistical significance.
Aug 29
2021
Chow et al., Journal of Thrombosis and Haemostasis, doi:10.1111/jth.15517 Association of Pre-Hospital Antiplatelet Therapy with Survival in Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis
19% lower mortality [p=0.005] and 3% lower ventilation [p=0.21]. PSM retrospective 6,781 hospitalized patients ≥50 years old in the USA who were on pre-hospital antiplatelet therapy (84% aspirin), and 10,566 matched controls, showing lower mortality with treatment.
Aug 18
2021
Ma et al., Drugs & Aging, doi:10.1007/s40266-021-00886-y Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults
9% lower mortality [p=0.12], 2% lower hospitalization [p=0.47], 9% more symptomatic cases [p=0.18], and 7% more cases [p=0.09]. UK Biobank retrospective 77,271 patients aged 50-86, showing no significant differences with aspirin use. Matching lead to different results for the gender vs. overall analysis, for example the overall result for cases was OR 1.07, howeve..
Jul 30
2021
Son et al., Medicine, doi:10.1097/MD.0000000000026670 Effect of aspirin on coronavirus disease 2019
24% lower mortality [p=0.52], 7% higher progression [p=0.8], and 11% more cases [p=0.21]. PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use.
Jul 30
2021
Abdelwahab et al., Clinical Drug Investigation, doi:10.1007/s40261-021-01061-2 Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study
8% higher ventilation [p=0.93]. Retrospective 225 hospitalized patients in Egypt, showing significantly lower thromboembolic events with aspirin treatment, but no significant difference in the need for mechanical ventilation.
Jul 20
2021
Vahedian-Azimi et al., Identification of Biomarkers, New Treatments, and Vaccines for COVID-19, doi:10.1007/978-3-030-71697-4_17 Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19
22% lower mortality [p=0.56] and 10% higher ICU admission [p=0.67]. Retrospective 587 COVID+ hospitalized patients in Iran, showing no significant differences in outcomes with aspirin treatment.
Jun 30
2021
Kevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008 Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
96% lower progression [p=0.0005]. Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen the..
Jun 17
2021
Oh et al., Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577 Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
1% lower mortality [p=0.95] and 12% fewer cases [p=0.04]. Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients.
May 26
2021
Pourhoseingholi et al., Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint) Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study
32% higher mortality [p=0.04]. Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing higher mortality with aspirin treatment. IR.MUQ.REC.1399.013.
May 26
2021
Pan et al., Heart & Lung, doi:10.1016/j.hrtlng.2021.04.010 Pre-hospital antiplatelet medication use on COVID-19 disease severity
13% higher mortality [p=0.63] and 2% higher combined mortality/intubation [p=0.93]. Retrospective 762 COVID+ hospitalized patients in the USA, 239 on antiplatelet medication (199 aspirin), showing no significant differences in outcomes. For more discussion see [sciencedirect.com].
May 19
2021
Sahai et al., Vascular Medicine, doi:10.1177/1358863X211012754 Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19
13% lower mortality [p=0.53]. PSM retrospective 1,994 PCR+ patients in the USA, not showing a significant difference in mortality with aspirin treatment.
Apr 30
2021
Elhadi et al., PLOS ONE, doi:10.1371/journal.pone.0251085 Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study
10% lower mortality [p=0.5]. Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
Apr 29
2021
Haji Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19
25% lower mortality [p=0.04]. Retrospective 991 hospitalized patients in Iran, showing lower mortality with aspirin treatment.
Apr 20
2021
Reese et al., medRxiv, doi:10.1101/2021.04.13.21255438 (Preprint) Cyclooxygenase inhibitor use is associated with increased COVID-19 severity
61% higher mortality [p<0.0001] and 309% higher severe cases [p<0.0001]. N3C retrospective 250,533 patients showing significantly higher mortality with aspirin use. Note that aspirin results were not included in the journal version or v2 of this preprint.
Apr 7
2021
Mulhem et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study
14% higher mortality [p=0.21]. Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06..
Apr 1
2021
Chow et al., Anesthesia & Analgesia, doi:10.1213/ANE.0000000000005292 Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019
47% lower mortality [p=0.02], 44% lower ventilation [p=0.007], and 43% lower ICU admission [p=0.007]. Retrospective 412 hospitalized patients, 98 treated with aspirin, showing lower mortality, ventilation, and ICU admission with treatment.
Mar 31
2021
Mura et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (date from earlier preprint) Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
15% lower mortality [p=0.08]. PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin..
Feb 23
2021
Merzon et al., The FEBS Journal, doi:10.1111/febs.15784 The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection
28% fewer cases [p=0.04] and 10% faster viral clearance [p=0.05]. Retrospective 10,477 patients in Israel, showing lower risk of COVID-19 cases with existing aspiring use.
Feb 12
2021
Liu et al., Medicine, doi:10.1097/MD.0000000000024544 Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19
75% lower mortality [p=0.03] and 2% slower viral clearance [p=0.94]. Retrospective PSM analysis of 232 hospitalized patients, 28 treated with aspirin, showing lower mortality with treatment. There was no significant difference in viral clearance.
Feb 11
2021
Osborne et al., PloS ONE, doi:10.1371/journal.pone.0246825 Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration
59% lower mortality [p<0.0001]. Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment.
Jan 21
2021
Meizlish et al., American Journal of Hematology, doi:10.1002/ajh.26102 Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis
48% lower mortality [p=0.004]. Retrospective 638 matched hospitalized patients in the USA, 319 treated with aspirin, showing lower mortality with treatment.
Dec 18
2020
Yuan et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198 Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease
4% lower mortality [p=0.89]. Retrospective 183 hospitalized patients in China, 52 taking low-dose aspirin prior to hospitalization, showing no significant difference with treatment.
Nov 29
2020
Formiga et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1 Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
3% higher mortality [p=0.48], 3% higher ventilation [p=0.75], and 4% higher ICU admission [p=0.65]. Retrospective 20,641 hospitalized patients in Spain, showing no significant difference in outcomes with existing aspirin use.
Nov 5
2020
Goshua et al., Blood, doi:10.1182/blood-2020-143349 Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
35% lower mortality [p=0.04], 49% higher ventilation [p=0.04], and 45% higher ICU admission [p=0.02]. PSM retrospective 2,785 hospitalized patients in the USA, showing lower mortality and higher ventilation and ICU admission with aspirin treatment.
Oct 31
2020
Husain et al., ResearchGate, doi:10.13140/RG.2.2.26038.93762/2 (Preprint) Beneficial effect of low dose aspirin (Acetyl salicylic acid) in adult Covid-19 patients: a retrospective observational study in Bangladesh
96% lower progression [p=0.001]. Retrospective 42 patients in Bangladesh, 11 treated with aspirin, showing fewer complications with treatment.
Sep 9
2020
Alamdari et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
28% higher mortality [p=0.52]. Retrospective 459 patients in Iran, 53 treated with aspirin, showing no significant difference with treatment.
Jul 14
2020
Wang et al., Journal of Hematology & Oncology, doi:10.1186/s13045-020-00934-x A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
58% lower mortality [p=0.43]. Retrospective 58 multiple myeloma COVID-19 patients in the USA, showing no significant difference with aspirin treatment.
May 7
2020
Holt et al., Journal of Hypertension, doi:10.1097/hjh.0000000000002515 Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients
34% higher combined mortality/ICU admission [p=0.09]. Retrospective 689 hospitalized COVID-19 patients in Denmark, showing higher risk of ICU/death with aspirin use in unadjusted results subject to confounding by indication.
May 4
2020
Huh et al., medRxiv, doi:10.1101/2020.05.04.20089904 (Preprint) Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea
71% fewer cases [p=0.001]. Retrospective database analysis of 65,149 in South Korea, showing significantly lower cases with existing aspirin treatment. The journal version of this paper does not present the aspirin results (only combined results for NSAIDs).
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit